| Company Name | Exchange | Ticker | Last Price | Total Analyst Coverage |
Upgrade/ Downgrade |
Analyst Name | Rating Company | Target Price |
Upside/ Downside (%) |
|---|---|---|---|---|---|---|---|---|---|
| Kirkland Lake Gold Inc | TSX | KGI | 3.33 | 10 | Upgrade to hold from sell | Adam Melnyk | Desjardins Securities | 3.75 | 12.6% |
| Silver Wheaton Corp | TSX | SLW | 25.01 | 19 | Initiate with overweight | John Bridges | JPMorgan | 34.06 | 36.2% |
| Golden Queen Mining Co Ltd | TSX | GQM | 1.67 | 6 | Initiate with buy | Jeffrey Wright | HC Wainwright & Co LLC | 2.75 | 64.7% |
| Matamec Explorations Inc | TSXV | MAT | 0.10 | 3 | Downgrade to hold from speculative buy | Luisa Moreno | Euro Pacific Canada Inc | 0.12 | 26.3% |
Desjardins Securities upgraded Kirkland Lake Gold Inc (TSX: KGI), a Canada-based gold mining company, to hold from sell with a price target of C$3.75, indicating an upside of 12.6% from current levels.
JPMorgan initiated coverage on Silver Wheaton Corp (TSX: SLW), a mining company generating its revenue primarily from the sale of silver, with an overweight rating assigning a 12-month price target of C$34.06, indicating an upside of 36.2% from current levels.
Coverage on Golden Queen Mining Co Ltd (TSX: GQM), engaged in exploring its mineral properties, was initiated with a buy rating at HC Wainwright & Co LLC with a 12-month price target of C$2.75, indicating an upside of 64.7% from current levels.
Euro Pacific Canada Inc downgraded Matamec Explorations Inc (TSXV: MAT), a mining exploration company focused on exploration of mineral properties for commercial exploitation, to hold from speculative buy lowering its price target to C$0.12 from C$0.22, indicating an upside of 26.3% from current levels.
| Company Name | Exchange | Ticker | Last Price |
Total Analyst Coverage |
Upgrade/ Downgrade |
Analyst Name | Rating Company | Target Price |
Upside/ Downside (%) |
|---|---|---|---|---|---|---|---|---|---|
| Huntsman Corp | NYSE | HUN | 25.52 | 15 | Upgrade to buy from neutral | John E Roberts | UBS | 32.00 | 25.4% |
| Select Medical Holdings Corp | NYSE | SEM | 12.59 | 9 | Upgrade to outperform from sector perform | Frank G Morgan | RBC Capital Markets | 21.00 | 66.8% |
| Agios Pharmaceuticals Inc | NASDAQ | AGIO | 35.48 | 5 | Upgrade to overweight from neutral | Dr Geoffrey Meacham | JPMorgan | 55.00 | 55.0% |
| UCP Inc | NYSE | UCP | 14.75 | 5 | Initiate with neutral | Brendan Lynch | Sidoti & Company LLC | 18.00 | 22.0% |
| Rambus Inc | NASDAQ | RMBS | 11.17 | 6 | Downgrade to neutral from buy | Matthew Galinko | Sidoti & Company LLC | 12.00 | 7.4% |
UBS upgraded Huntsman Corp (NYSE: HUN), a manufacturer of differentiated organic chemical products and inorganic chemical products, to buy from neutral raising its price target to $32.00 from $24.00, indicating an upside of 25.4% from current levels. The rating firm believes that the accretion from the Rockwood asset acquisition and a bottom in TiO2 prices will act as strong catalyst for the stock and views the current valuation of the stock as very attractive.
Select Medical Holdings Corp (NYSE: SEM), an operator of both specialty hospitals and outpatient rehabilitation clinics, was upgraded to outperform from sector perform at RBC Capital Markets increasing its price target to $21.00 from $9.00, indicating an upside of 66.8% from current levels. Recently, SEM completed its previously announced private placement worth $110.0 million representing 6.375% senior notes due 2021. The company intends to use the net proceeds to repurchase 10 million shares of Holdings’ common stock from Welsh, Carson, Anderson & Stowe IX, L.P. and WCAS Capital Partners IV, L.P.
JPMorgan upgraded Agios Pharmaceuticals Inc (NASDAQ: AGIO), a biopharmaceutical company engaged in discovering and developing therapeutics in the field of cancer metabolism, to overweight from neutral raising its price target to $55.00 from $40.00, indicating an upside of 55% from current levels. Recently, AGIO reported that an experimental drug being developed by the company showed promising anti-cancer activity in a tiny Phase I study of patients with relapsed acute myeloid leukemia (AML).
Sidoti & Company LLC initiated coverage on UCP Inc (NYSE: UCP), a homebuilder and land developer, with a neutral rating assigning a 12-month price target of $18.00, indicating an upside of 22% from current levels.
However, Sidoti downgraded Rambus Inc (NASDAQ: RMBS), a technology solutions company engaged in inventing, developing, offering and licensing solutions that challenge and enable its customers to create the future, to neutral from buy with a price target of $12.00, indicating an upside of 7.4% from current levels.
